Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3548 participants.
Also called NCT04499859
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,548 participants
- Sponsor
- Kiyuk Chang, MD,PhD
- Registry
-
NCT04499859
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT04499859. Randomized; no masking; primary purpose treatment. Start 2020-10-01 (actual); primary completion 2026-08-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI
- Acronym
- ROSUZET-AMI
- Condition
- Myocardial Infarction
- Condition
- Statin Adverse Reaction
- Condition
- HMG-CoA Reductase Inhibitor Toxicity
- Intervention (Drug)
- Ezetimibe 10mg + Rosuvastatin 5mg
- Intervention (Drug)
- Rosuvastatin 20mg
- Lead sponsor
- Kiyuk Chang, MD,PhD
Record details
- Record id
cardio:ct-nct04499859- Content hash
5dd29f3c4a54ed32c30b2b0dc8c62477c7957c6cc6568ee04e24374b93c4b389